CureDuchenne Ventures, LLC 3
3 · Dyne Therapeutics, Inc. · Filed Sep 16, 2020
Insider Transaction Report
Form 3
CureDuchenne Ventures, LLC
10% Owner
Holdings
Series A Preferred Stock
→ Common Stock (602,972 underlying)
Footnotes (1)
- [F1]The Series A Preferred Stock is convertible into common stock on a 3.3169-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.